​

Achieve Life Sciences Stock (NASDAQ:ACHV)

ForecastRevenueOwnershipFinancialsChartTranscripts
Achieve Life Sciences by TradingView

Previous Close

$4.61

52W Range

$1.84 - $5.78

50D Avg

$4.32

200D Avg

$3.19

Market Cap

$250.15M

Avg Vol (3M)

$1.24M

Beta

1.70

Div Yield

-

ACHV Company Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

25

IPO Date

Oct 12, 1995

Website

ACHV Performance

ACHV Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-27.25M$-40.80M
Net Income$-39.83M$-29.82M$-41.88M
EBITDA-$-26.73M$-40.33M
Basic EPS$-1.24$-1.50$-3.95
Diluted EPS$-1.24$-1.50$-3.95

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 06, 25 | 8:30 AM
Q2 25Aug 08, 25 | 8:30 AM
Q1 25May 13, 25 | 8:30 AM

Peer Comparison

TickerCompany
ARCTArcturus Therapeutics Holdings Inc.
CAPRCapricor Therapeutics, Inc.
ALLOAllogene Therapeutics, Inc.
HUMAHumacyte, Inc.
AVIRAtea Pharmaceuticals, Inc.
VNDAVanda Pharmaceuticals Inc.
SGMTSagimet Biosciences Inc.
VYGRVoyager Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.
IMRXImmuneering Corporation